BI-10773 (Empagliflozin) Mechanism of Action: SGLT2 Inhibition in Cardiomyocytes Research

BI-10773 (Empagliflozin) MOA:Targeting SGLT2/NHE1 Pathway for Heart Failure

🎯 check BI-10773 (Empagliflozin) product page

BI-10773 (Empagliflozin) is a potent, highly selective SGLT2 inhibitor. It affects renal glucose reabsorption pathways by competitively blocking the sodium-glucose co-transporter 2 in the proximal tubule, promoting urinary glucose excretion and lowering blood glucose levels.

Primary Applications and Mechanism of Action